JP2021534121A5 - - Google Patents

Info

Publication number
JP2021534121A5
JP2021534121A5 JP2021506746A JP2021506746A JP2021534121A5 JP 2021534121 A5 JP2021534121 A5 JP 2021534121A5 JP 2021506746 A JP2021506746 A JP 2021506746A JP 2021506746 A JP2021506746 A JP 2021506746A JP 2021534121 A5 JP2021534121 A5 JP 2021534121A5
Authority
JP
Japan
Prior art keywords
sequence
sequence shown
amino acid
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021506746A
Other languages
English (en)
Japanese (ja)
Other versions
JP7428696B2 (ja
JP2021534121A (ja
Filing date
Publication date
Priority claimed from GBGB1813137.5A external-priority patent/GB201813137D0/en
Application filed filed Critical
Publication of JP2021534121A publication Critical patent/JP2021534121A/ja
Publication of JP2021534121A5 publication Critical patent/JP2021534121A5/ja
Priority to JP2024000815A priority Critical patent/JP7728035B2/ja
Application granted granted Critical
Publication of JP7428696B2 publication Critical patent/JP7428696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506746A 2018-08-10 2019-08-12 抗体による癌治療 Active JP7428696B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000815A JP7728035B2 (ja) 2018-08-10 2024-01-05 抗体による癌治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1813137.5A GB201813137D0 (en) 2018-08-10 2018-08-10 Cancer treatment with an antibody
GB1813137.5 2018-08-10
PCT/EP2019/071627 WO2020030827A1 (en) 2018-08-10 2019-08-12 Cancer treatment with an antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000815A Division JP7728035B2 (ja) 2018-08-10 2024-01-05 抗体による癌治療

Publications (3)

Publication Number Publication Date
JP2021534121A JP2021534121A (ja) 2021-12-09
JP2021534121A5 true JP2021534121A5 (enExample) 2022-08-18
JP7428696B2 JP7428696B2 (ja) 2024-02-06

Family

ID=63667034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506746A Active JP7428696B2 (ja) 2018-08-10 2019-08-12 抗体による癌治療
JP2024000815A Active JP7728035B2 (ja) 2018-08-10 2024-01-05 抗体による癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000815A Active JP7728035B2 (ja) 2018-08-10 2024-01-05 抗体による癌治療

Country Status (12)

Country Link
US (1) US11858982B2 (enExample)
EP (1) EP3833404A1 (enExample)
JP (2) JP7428696B2 (enExample)
KR (1) KR20210088523A (enExample)
CN (1) CN112770786B (enExample)
AU (1) AU2019319092B2 (enExample)
BR (1) BR112021002435A2 (enExample)
GB (1) GB201813137D0 (enExample)
IL (1) IL280421B2 (enExample)
MX (1) MX2021001604A (enExample)
TW (1) TW202014437A (enExample)
WO (1) WO2020030827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250025553A1 (en) 2021-11-18 2025-01-23 Medannex Ltd. Combination therapy for cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219299A1 (en) 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
US20040219572A1 (en) 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
EP1670510A1 (en) 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
JP5139058B2 (ja) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
CN100571785C (zh) * 2006-09-06 2009-12-23 中国医学科学院北京协和医院 Annexin A3与癌症的铂类化疗药物耐药性的相关性
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
EP2580241B1 (en) * 2010-06-09 2020-11-04 Queen Mary & Westfield College, University of London Annexin 1 antibody
CN102898527B (zh) 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
KR20150029457A (ko) 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도
US20160291025A1 (en) 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
US20210292400A1 (en) 2018-05-17 2021-09-23 Yiping W. Han Methods for treating, preventing and detecting the prognosis of colorectal cancer
US20210353721A1 (en) 2018-08-07 2021-11-18 The Brigham And Women's Hospital, Inc. Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1
US20200171165A1 (en) 2018-11-30 2020-06-04 Proteogenomics Research Institute for Systems Medicine Enhanced targeted delivery of therapeutic agents

Similar Documents

Publication Publication Date Title
JP2021525087A5 (enExample)
JP2024167313A5 (enExample)
JP2019110906A5 (enExample)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP6962915B2 (ja) 改善されたtnf結合因子
JP2017530722A5 (enExample)
JP2017529838A5 (enExample)
JP2017535257A5 (enExample)
JP2021527714A5 (enExample)
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
RU2017104813A (ru) Молекулы со специфичностью к cd45 и cd79
JP2017506067A5 (enExample)
JP2014522850A5 (enExample)
JP2013056885A5 (enExample)
JP2014158469A5 (enExample)
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2017507652A5 (enExample)
JP2014522843A5 (enExample)
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
JP2013519364A5 (enExample)
JP2011207882A5 (enExample)
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
JP2020522280A5 (enExample)
JP2023518153A5 (enExample)
JP2018536632A5 (ja) B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子